Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro

Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro

Background: Intrahepatic cholangiocarcinoma (ICC) is a malignant carcinoma with high rate of mortality. The current treatment is ineffective with poor survival time. Therefore, there is an urgent need for effective therapeutic drug regimens. The multi-target tyrosine kinase inhibitor (TKI) anlotinib...

Full description

Bibliographic Details
Main Authors: An, G. (Author), Fan, S. (Author), Fan, X. (Author), Gao, T. (Author), Ge, Y. (Author), Liu, H. (Author), Liu, J. (Author), Xiao, Z. (Author), Yan, R. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
anlotinib
antineoplastic activity
antineoplastic agent
Antineoplastic Agents
apoptosis
Apoptosis
Article
bile duct carcinoma
cancer inhibition
caspase 3
catequentinib
cell cycle arrest
Cell Line, Tumor
cell viability
cell viability assay
Cholangiocarcinoma
combination drug therapy
concentration response
controlled study
Deoxycytidine
doxecitine
drug effect
drug potentiation
Drug Therapy, Combination
enzyme degradation
flow cytometry
G1 phase cell cycle checkpoint
G1 Phase Cell Cycle Checkpoints
gemcitabine
HCCC-9810 cell line
human
human cell
Humans
in vitro study
indole derivative
Indoles
intrahepatic cholangiocarcinoma
metabolism
nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase
protein expression
quinoline derivative
Quinolines
RBE cell line
synergistic
tumor cell line
Western blotting
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items